FDA Approves Unknown Drug — BAYER HEALTHCARE

On July 30, 2019, the FDA granted approval for BAYER HEALTHCARE's generic drug NDA212099, a move that is expected to provide cost-effective competition within the targeted therapeutic category and bolster the company’s specialty portfolio. This regulatory clearance allows for the commercial launch of the generic formulation, potentially accelerating market share gains against branded counterparts while driving incremental revenue streams for Bayer.